Abstract: A new pharmaceutical composition is disclosed useful in the treatment of neuroviruses and formulated as an injectable solution. The pharmaceutical composition is composed of the calcium and sodium double salt of ethylene diamine tetracetic acid, associated with calcium gluconate as a source of Ca.sup.2+ ions, and cysteine or its HC1 salt, wherein the weight ratio of the ingredients ranges from 8-12 g to 0.3 to 1 g to 0.05 to 0.2 g respectively per 100 ml of water.
Type:
Grant
Filed:
October 10, 1985
Date of Patent:
August 25, 1987
Assignee:
Centrala Industriala de Medicamente Cosmetice Coloranti Si Lacuri
Abstract: Cattle breeding herds are managed for accelerated time-controlled calving, using groups of cows predicted to calve within a period of 10 days, 1000 to 10,000 units of purified porcine relaxin are administered intramuscularly or intracervically. Auxiliary agents may also be administered such as methasone or dexamethasone. Within the selected group, parturition can be limited to time periods as short as 24 to 48 hours. Further, parturition can be accelerated from 2 to 10 days. These benefits are obtained without adverse side effects such as retained placenta or dystocia.
Type:
Grant
Filed:
July 25, 1985
Date of Patent:
August 11, 1987
Assignee:
Iowa State University Research Foundation, Inc.
Abstract: A method of treatment for patients suffering from cerebral ischemia is provided by administering an opioid peptide. Particulary preferred is the administration of dynorphin, or dynorphin-related peptides, in the acid or amidated form. Practice of the invention is useful in prolonging survival.
Type:
Grant
Filed:
May 20, 1985
Date of Patent:
August 4, 1987
Assignees:
Yoshio Hosobuchi, Nancy M. Lee, Horace H. Loh, Jaw-Kang Chang
Inventors:
Yoshio Hosobuchi, Nancy M. Lee, Horace H. Loh, Jaw-Kang Chang
Abstract: A storage-stable sucralfate-containing preparation which maintains its ability, even after extended periods of time, to form a viscous, sticky, paste-like material in the presence of gastric secretions is disclosed as well as the method of making same.
Abstract: Hair-cosmetic compositions for improving the structure, resilience and strength of hair comprising a content of onic acids derived from aldohexoses or disaccharides containing a free aldehyde function and/or their .gamma.- or .delta.-lactones and a method of improving the structure and strength of hair, particularly hair which has been adversely affected by cosmetic treatments such as dyeing, bleaching, permanent waving, etc.
Type:
Grant
Filed:
January 8, 1986
Date of Patent:
May 19, 1987
Assignee:
Henkel Kommanditgesellschaft auf Aktien
Inventors:
Detlef Hollenberg, Hans-Wolfgang Cortekar, Karl Giede, Horst Hoffkes
Abstract: Diuretic and natriuretic extracts, which have been characterized as peptide in nature, have been obtained by homogenization of mammalian heart atria with an aqueous solution of a lower carboxylic acid and may be prepared synthetically. After precipitation of impurities by pH adjustment, the extract may be further purified chromatographically. Extracts injected into test rats resulted in 30-40 fold increases in sodium and chloride excretions within 5-10 minutes of injection. Urine volume rose 10-15 fold and potassium excretion doubled. The response was complete in 20 minutes and no similar changes in renal function were observed following injection of a similarly obtained ventricular extract.
Abstract: A solid fibrinogen formulation is described, which formulation contains, in addition to fibrinogen, a substance containing the urea or guanidine radical, and a process for its preparation. This formulation is used for the preparation of a fibrinogen solution which is suitable as an adhesive for human and animal tissue and as a fibrinogen concentrate for intravenous administration.
Type:
Grant
Filed:
August 10, 1984
Date of Patent:
March 17, 1987
Assignee:
Behringwerke Aktiengesellschaft
Inventors:
Peter Fuhge, Norbert Heimburger, Hans-Arnold Stohr, Wolfgang Burk
Abstract: The present invention relates to animal feed block compositions containing a growth promoter, such as avoparcin, and an organic or mineral acid. The feed blocks of this invention exhibit improved potency retention of the growth promoter. Further provided are methods for enhancing the growth promoter potency retention of such feed blocks by adjusting the pH of the feed blocks below pH 7 with the organic or mineral acid.
Abstract: Diuretic and natriuretic extracts, at least partially characterized as peptides, have been obtained by homogenization of mammalian heart atria with an aqueous solution of a lower carboxylic acid. After precipitation of impurities by pH adjustment, the extract may be further purified chromatographically. Extracts injected into text rats resulted in 30-40 fold increases in sodium and chloride excretions within 5-10 minutes of injection. Urine volume rose 10-15 fold and potassium excretion doubled. The response was complete in 20 minutes and no similar changes in renal function were observed following injection of a similarly obtained ventricular extract.
Abstract: A pharmaceutical composition comprising an amount, effective for inhibiting platelet aggregation, of guanosine monophosphate represented by the following formula ##STR1## wherein one of X, Y and Z represents a H.sub.2 PO.sub.3 group and the remaining two of these represent a hydrogen atom,or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable diluent or carrier.
Abstract: A new biologically active polypeptide hormone has been isolated from calf thymosin fraction 5 and has been given the designation thymosin alpha.sub.11. The peptide contains seven additional amino acid residues at the carboxy terminus when compared to thymosin alpha.sub.1. Thymosin alpha.sub.11 is one of several peptides present in thymosin fraction 5 which participate in the regulation, differentiation and function of thymic dependent lymphocytes (T cells). The new peptide is approxomately 16 times as potent in the protection of subject animals against opportunistic infections as thymosin fraction 5 and approximately equal in potency to thymosin alpha.sub.1.
Abstract: N-acyl derivatives of dipeptides of the formulaX-CO-L-Leu-NH-CH.sub.2 -CO-Rwhere X and R have the meanings given in the description, are useful for the therapy of disorders.
Abstract: Novel N-acyl derivatives of peptides related to L-pro-L-leu-gly-NH.sub.2, melanocyte stimulating hormone-release inhibiting factor (MIF), and therapeutic compositions which are useful for the treatment of depression.
Abstract: A method of preparing an anti-breast tumor compound comprised of a toxic metal bound to the blood protein transferrin is disclosed which has superior therapeutic properties. When monomeric transferrin is bound to cis-Dichlorodiammineplatinum (II), a chemotherapeutic agent is produced which specifically attacks and kills rapidly multiplying breast tumor cells without damaging normal cells. In addition, the body's immune defenses against foreign substances are substantially not activated. In preferred embodiments, 1.8-2.2 atoms of platinum are bound to each molecule of transferrin. The platinum-transferrin is prepared by first protecting the sulfhydro groups on essentially iron free transferrin with an excess of cystine in solution. Cis-dichlorodiammine platinum (II) is then reacted with the iron-free transferrin in the presence of bicarbonate anion.
Abstract: A process for heating and simultaneously agitating a plasma protein solution in the presence of a polyol, a surface active agent and a chelating agent. Said process inactivates viruses in said solution while preserving the physical and biological properties of said plasma protein.
Type:
Grant
Filed:
December 21, 1984
Date of Patent:
April 29, 1986
Assignee:
Armour Pharmaceutical Co.
Inventors:
Ricardo H. Landaburu, Godfrey W. Amphlett, Roy E. Branson, Arthur B. Shaw
Abstract: Immunostimulatory peptide is isolated from bovine thymus tissue and is useful to treat mammals and birds at risk from viral or fungal infections or other trauma.
Abstract: A method of increasing the clearance of particles from the blood stream of a vertebrate, which comprises administering to a vertebrate having a surplus of particles in the blood stream of the vertebrate an amount of somatostatin sufficient to increase phagocytosis in the vertebrate, is disclosed.
Abstract: CGRP (calcitonin-gene-related peptide) has the formula: ##STR1## A related peptide has the residue Lys instead of Glu in the 35-position. CGRP or this homolog or pharmaceutically acceptable salts thereof, dispersed in a pharmaceutically acceptable liquid or solid carrier, can be administered to mammals, including humans, to influence memory, mood and pain appreciation and to achieve a substantial lowering of blood pressure or gastric acid secretion over an extended period of time. They also may be administered to affect ingestion behavior, taste and sensory perception.
Type:
Grant
Filed:
July 8, 1983
Date of Patent:
July 23, 1985
Assignee:
The Salk Institute for Biological Studies
Inventors:
Ronald M. Evans, Larry Swanson, Wylie W. Vale, Jr., Michael G. Rosenfeld, Susan G. Amara, Marvin R. Brown, Jean E. F. Rivier
Abstract: A process for the production of tumor angiogenetic factor and the production of antigens from a purified angiogenetic factor is shown in the present invention. The production of tumor angiogenetic factor is accomplished by injecting a material of a suitable composition to initiate production of fluid in the cavity of a living animal by inciting an inflammatory response in the cavity tissues, which response is characterized by the production of granulation tissue comprised mostly of new capillaries. After the body cavity is partly filled with the exudate, the fluid is tapped out of the cavity and purified to yield angiogenetic factor. The production of antigens is accomplished by dissolving the purified angiogenetic factor in an equal volume of distilled water, reacting the dissolved angiogenetic factor in the distilled water with a gluteraldehyde solution for at least twelve (12) hours and lyophilizing resulting mixture for storage.
Abstract: A method for producing a human epidermal growth factor in high yield and high purity by adding particles of an aluminum or magnesium silicate of the formula z.2 (or 6) SiO.sub.2.xH.sub.2 O where Z is Al.sub.2 O.sub.3 or 2MgO and x is the number of water molecules in each molecule of the compound, to human urine under neutral to acid conditions to adsorb the factor on the particles and then eluting the factor with an alkaline solution.